I Fell Down the Ergothioneine Rabbit Hole. Here's What I Found.

I recently fell down the ergothioneine rabbit hole, and I'm not sure I want to come back up.

Ergothioneine is a sulfur-containing amino acid produced almost exclusively by fungi and soil bacteria. It's been called a "longevity vitamin" in some research circles, though that framing undersells how specifically the body seems to rely on it. The research links low levels to Alzheimer's, Parkinson's, cardiovascular disease, cognitive decline, and now, something I wasn't expecting, period pain.

That last one is what started the rabbit hole. And it's worth going into in some detail, because the mechanism behind it reveals something much bigger than menstrual health.

A new clinical trial recruited 40 women aged 18 to 30 with primary dysmenorrhea, which is period pain without an underlying condition like endometriosis. Half took 120mg of ergothioneine daily across three consecutive menstrual cycles. Half took a placebo. Neither group knew which they were getting.

At baseline, the ergothioneine group reported an average peak pain score of 4.8 out of 10. By cycle one it had dropped to 4.1. By cycle two, 3.6. By cycle three, 2.3. That's more than half, achieved progressively, with each cycle showing greater improvement than the last. The placebo group showed no significant change. 84% of women in the ergothioneine group achieved 50% or greater pain reduction by the final cycle, compared to 35% in placebo. No adverse events were reported in either group.

Those are striking numbers. But what I find fascinating is the mechanism, because it's completely unlike anything ibuprofen does.

The standard model of period pain goes like this. Just before menstruation, falling progesterone triggers a release of arachidonic acid, which the body converts into prostaglandins. Elevated prostaglandins cause uterine contractions strong enough to compress nearby blood vessels, briefly cutting off oxygen supply to the muscle tissue. That oxygen deprivation (ischemia) is the source of the cramping. Ibuprofen blocks prostaglandin production, and that's why it helps.

It works acutely. But it's acting on the symptom, not on the upstream conditions that made those prostaglandins so destructive in the first place.

What the prostaglandin model leaves out is what happens in the tissue itself when it becomes oxygen-deprived. Ischemic cells generate reactive oxygen species, commonly called free radicals, and elevated free radicals in the uterine environment drive a secondary cascade: more oxidative damage to local tissue, more inflammation, more pain sensitisation. Multiple studies have found that women with more severe period pain have significantly higher oxidative stress markers and depleted antioxidant reserves in uterine tissue. The pain isn't just about prostaglandins. It's about the cellular environment those prostaglandins are detonating in.

This is where ergothioneine enters, and where things get interesting.

The researchers in this trial measured four classical inflammatory biomarkers (IL-6, TNF-alpha, IL-1beta, and prostaglandin F2alpha) at baseline and after the third cycle. None of them changed significantly in either group, and none correlated with pain reduction. Ergothioneine cut pain in half without moving any of the markers that ibuprofen targets. It's working through a different pathway entirely.

That pathway runs through the mitochondria. Ergothioneine is absorbed via a highly specific transporter called OCTN1. Unlike most antioxidants that circulate passively in the bloodstream, ergothioneine is actively transported into cells and concentrated in the mitochondria, precisely where free radical production is highest during ischemia. And crucially, OCTN1 expression is upregulated in response to tissue damage and inflammation. The body specifically increases its ergothioneine import capacity in stressed tissue. It's not a passive defence, it's an adaptive, demand-responsive system.

This explains the progressive nature of the effect. You're restoring the redox balance of the cellular environment, cycle by cycle, as ergothioneine accumulates and tissue becomes more resilient to the ischemic insult. The compound becomes more effective as it builds up in cells. Lead researcher Guohua Xiao described the mechanism as neutralising free radicals directly at the source of the cellular stress, before the systemic inflammatory cascade is even triggered.

That's a fundamentally different mode of action from any painkiller currently on the market.

Here's the part that I think doesn't make it into most coverage of this study, and it's the part that got me obsessed.

Ergothioneine is produced almost exclusively by fungi. It enters the human food chain through mushrooms (the most concentrated source by far), through plants that absorb it from soil fungal networks, and through animals grazing on mycorrhizally-active pasture. The body has built dedicated infrastructure to prioritise it: a specific transporter to import it, kidneys that reabsorb it rather than excreting it, and active mechanisms to maintain blood levels.

That level of investment in a single compound is unusual. It suggests the body evolved in a world where ergothioneine was a reliable, abundant input, and oriented its oxidative stress defences accordingly.

Typical dietary intake for someone not regularly eating mushrooms is around 5mg per day. The therapeutic dose in this trial was 120mg.

That gap tells a story. Industrial agriculture disrupts mycorrhizal fungal networks through tillage and synthetic phosphorus application, reducing ergothioneine content in crops. Feedlot cattle, eating grain from tilled monocultures, contain roughly 60% less ergothioneine than grass-fed animals grazing on mycorrhizally-active pasture. Hydroponic produce contains essentially none. We have constructed a food system that systematically strips out a compound the body treats as essential, and then we wonder why conditions driven by oxidative stress keep rising.

Primary dysmenorrhea is one data point in that picture. Neurodegeneration, cardiovascular disease, frailty, and cognitive decline are others. Research has found that low plasma ergothioneine predicts cognitive impairment before symptoms appear. The pattern across these conditions is consistent: depleted ergothioneine, compromised oxidative stress response, and tissue that can't handle metabolic insult.

These conditions didn't come from nowhere. We stripped out something the body relied on, and this is part of the result.

A few honest caveats before the practical part. This is a 40-person pilot trial from a single centre in China, funded by the ingredient manufacturer, not yet peer-reviewed, and retrospectively registered. It tells us there's a signal worth taking seriously. It doesn't tell us the optimal dose, whether the effect holds in larger populations, or what the long-term picture looks like. A larger multicentre trial is planned, and that will be the real test.

What this trial does establish is a coherent, mechanistically distinct intervention for a condition affecting hundreds of millions of women that has been largely underserved by research. And the safety profile matters here. Long-term NSAID use carries real risks including elevated cardiovascular events, kidney damage, and gastric ulcers. Ergothioneine has GRAS (Generally Recognised as Safe) status from the FDA at doses up to 30mg per day for food use, and showed zero adverse events at 120mg across three months in this trial.

If you're looking to increase your intake from food, mushrooms are by a significant margin the best source. Oyster, shiitake, and king oyster varieties are particularly well-studied for ergothioneine content. From a supplement perspective, look for dual water and alcohol extraction, which is important because ergothioneine is water-soluble and needs proper extraction to be bioavailable from the mushroom matrix. Crude powders are far less reliable on this front.

Based on the research, lion's mane and reishi contain the highest ergothioneine concentrations among medicinal mushrooms.

The thing about ergothioneine that keeps pulling me back is what it represents beyond its own mechanism.

Your body doesn't just tolerate fungal compounds. It depends on them. It built specific infrastructure to absorb them, retain them, and concentrate them in the cells that need them most. The fungi and the human body have been co-evolving for hundreds of millions of years, and the traces of that relationship are written into our biochemistry at a level that industrialised nutrition has only recently begun to disrupt.

Period pain is not an inevitable feature of being a woman. Cognitive decline is not an inevitable feature of getting older. Some of what we've accepted as normal is, at least in part, a consequence of a food system that broke our relationship with fungi.

Restoring that relationship is not a silver bullet. But studies like this one suggest it might be a piece of the picture we've been missing, hiding in plain sight in the mushrooms we stopped eating.

This study is a preprint and has not yet undergone peer review. Full paper: medRxiv doi.org/10.64898/2026.03.26.26349375